A lentiviral vector-based therapeutic cancer vaccine (gene therapy immunotherapy) encoding HPV16/18 E6/E7 antigens. Delivered by intramuscular injection, it transduces antigen-presenting cells to express E6/E7, leading to MHC I/II presentation and priming/expansion of HPV-specific CD8+ and CD4+ T-cell responses to kill HPV-positive tumor cells in cervical or oropharyngeal squamous cancers. The study evaluates 1–2 IM doses for safety, immunogenicity, and preliminary efficacy.
Non‑integrating lentiviral vector encoding detoxified HPV16/18 E6/E7 antigens is injected intramuscularly, transducing antigen‑presenting cells to express E6/E7. The antigens are processed and displayed on MHC I/II, priming and expanding HPV‑specific CD8+ cytotoxic and CD4+ helper T‑cell responses that recognize and kill HPV‑positive tumor cells.
YES
INDIRECT
The vaccine transduces APCs to present HPV16 E6/E7 peptides, priming HPV-specific CD8+ T cells that recognize E6-derived peptides on MHC I of tumor cells and kill them via perforin/granzyme-mediated cytolysis (with CD4+ T-cell help).
A lentiviral vector-based therapeutic cancer vaccine (gene therapy immunotherapy) encoding HPV16/18 E6/E7 antigens. Delivered by intramuscular injection, it transduces antigen-presenting cells to express E6/E7, leading to MHC I/II presentation and priming/expansion of HPV-specific CD8+ and CD4+ T-cell responses to kill HPV-positive tumor cells in cervical or oropharyngeal squamous cancers. The study evaluates 1–2 IM doses for safety, immunogenicity, and preliminary efficacy.
Non‑integrating lentiviral vector encoding detoxified HPV16/18 E6/E7 antigens is injected intramuscularly, transducing antigen‑presenting cells to express E6/E7. The antigens are processed and displayed on MHC I/II, priming and expanding HPV‑specific CD8+ cytotoxic and CD4+ helper T‑cell responses that recognize and kill HPV‑positive tumor cells.
YES
INDIRECT
Vaccine-transduced APCs present E7 peptides to prime HPV16 E7–specific CD8+ T cells; these CTLs recognize E7-derived peptides on MHC I of HPV-positive cells and kill them via perforin/granzyme-mediated cytolysis (and Fas–FasL apoptosis).
A lentiviral vector-based therapeutic cancer vaccine (gene therapy immunotherapy) encoding HPV16/18 E6/E7 antigens. Delivered by intramuscular injection, it transduces antigen-presenting cells to express E6/E7, leading to MHC I/II presentation and priming/expansion of HPV-specific CD8+ and CD4+ T-cell responses to kill HPV-positive tumor cells in cervical or oropharyngeal squamous cancers. The study evaluates 1–2 IM doses for safety, immunogenicity, and preliminary efficacy.
Non‑integrating lentiviral vector encoding detoxified HPV16/18 E6/E7 antigens is injected intramuscularly, transducing antigen‑presenting cells to express E6/E7. The antigens are processed and displayed on MHC I/II, priming and expanding HPV‑specific CD8+ cytotoxic and CD4+ helper T‑cell responses that recognize and kill HPV‑positive tumor cells.
YES
INDIRECT
The vaccine primes HPV18 E6–specific T-cell responses; activated CTLs recognize E6-derived peptides on MHC I of HPV+ tumor cells and kill them via perforin/granzyme-mediated cytolysis.
A lentiviral vector-based therapeutic cancer vaccine (gene therapy immunotherapy) encoding HPV16/18 E6/E7 antigens. Delivered by intramuscular injection, it transduces antigen-presenting cells to express E6/E7, leading to MHC I/II presentation and priming/expansion of HPV-specific CD8+ and CD4+ T-cell responses to kill HPV-positive tumor cells in cervical or oropharyngeal squamous cancers. The study evaluates 1–2 IM doses for safety, immunogenicity, and preliminary efficacy.
Non‑integrating lentiviral vector encoding detoxified HPV16/18 E6/E7 antigens is injected intramuscularly, transducing antigen‑presenting cells to express E6/E7. The antigens are processed and displayed on MHC I/II, priming and expanding HPV‑specific CD8+ cytotoxic and CD4+ helper T‑cell responses that recognize and kill HPV‑positive tumor cells.
YES
INDIRECT
The vaccine transduces APCs to present HPV18 E7 peptides, priming E7-specific CD8+ T cells that recognize E7-derived peptides on MHC I of tumor cells and kill them via perforin/granzyme-mediated cytotoxicity.
Allogeneic cord blood–derived natural killer cell therapy engineered to express an anti-TROP2 chimeric antigen receptor and IL-15; CAR engagement of TROP2 triggers NK cytotoxicity while IL-15 signaling sustains survival, proliferation, and in vivo persistence.
Allogeneic cord blood–derived NK cells engineered to express an anti-TROP2 chimeric antigen receptor and IL-15. CAR recognition of TROP2 on tumor cells triggers NK activation and cytotoxicity (perforin/granzyme-mediated lysis and cytokine release), while IL-15 autocrine signaling sustains NK survival, proliferation, and in vivo persistence; an inducible caspase-9 safety switch allows drug-mediated ablation if needed.
YES
DIRECT
CAR-NK cells bind TROP2 on target cells, triggering NK activation and degranulation with perforin/granzyme-mediated lysis/apoptosis (with contributory cytokine effects).